Novavax has partnered with AGC Biologics of Denmark to manufacture an adjuvant for its COVID-19 vaccine candidate NVX-CoV2373.

The adjuvant enhances the immune response to the vaccine and stimulates high levels of neutralizing antibodies to the virus. AGC Biologics will scale up production of the Matrix-M adjuvant to increase Novavax’s capacity to deliver vaccine doses this year.

The Maryland-based company has begun a phase 1/2 trial of NVX‑CoV2373 in Australia and expects to release phase 1 results in July.